BMS-986504 for MTAP-deficient relapsed mesothelioma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called BMS-986504 in patients whose mesothelioma (a cancer of the lung lining) has come back after previous treatment and has a specific genetic marker called MTAP deficiency. The drug may help by targeting cancer cells with this marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of malignant mesothelioma that has progressed despite at least one prior cancer treatment
- Your tumor must have MTAP deficiency (a specific genetic feature) confirmed by a specialized blood or tissue test
- Good overall health and functional status (able to do light activity; ECOG score 0–1)
- Adequate blood counts, liver and kidney function to safely tolerate the study drug
- No active brain cancer, active infection, or uncontrolled heart disease
- Willing and able to take an oral medication and provide blood samples; women and men must use contraception for 6 months after treatment ends
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
This trial tests a new drug (BMS-986504) combined with an existing chemotherapy (pemetrexed) for advanced solid cancers that have a specific genetic change called MTAP deletion. The trial aims to see if this combination can slow or stop tumor growth in patients whose cancer has progressed despite prior treatment.
This study tests a new drug, BMS-986504, to see how it is processed and removed from the body in people with certain advanced solid tumors. It is for patients whose cancer has a specific genetic change (MTAP deletion) and who have no other good treatment options.
This study tests an experimental oral medication (navlimetostat) for people with advanced lung cancer whose tumors have a specific genetic change called an MTAP deletion. It’s for those whose cancer has progressed after earlier treatments.
This trial tests a new drug (BMS-986504) combined with standard chemotherapy or immunotherapy for three types of advanced solid tumors: mesothelioma, gastroesophageal cancer, or bladder cancer. It may be an option if your tumor has a specific genetic change called MTAP deletion.
Hear when a new Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.